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ABSTRACT 
Although hysteroscopy is currently the undisputed gold standard for the examination of the uterine cavity in women with 
suspected endometrial cancer, it remains controversial as a procedure that can enhance metastasis spread. Endometrial 
cancer cells may shed during hysteroscopy and be passively transported with fluid flow into the peritoneal cavity. The 
paper presents the review of current knowledge regarding the risk of neoplasm metastases in women who had diagnostic 
hysteroscopy and the conditions that have to be met for the procedure to be safe. We searched PubMed, Ovid, Medline 
and Scopus databases for data published in the years 1985–2017. The following browsing criteria, the  “MeSH headings”: 
hysteroscopy, endometrial cancer, intraperitoneal or metastatic spread were used to find relevant papers. Based on the 
current data analysis we conclude that: 1) diagnostic hysteroscopy performed in women with endometrial cancer, especially 
in its early stages, is a very useful, efficient and safe diagnostic method and 2) the distension media used for endoscopic 
procedures in the uterine cavity must be strictly controlled for relatively low pressures to prevent the increase in risk of 
endometrial cancer intraperitoneal spread.
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INTRODUCTION
One of the most common gynecological symptoms in 
women is abnormal uterine bleeding (AUB). Although the un-
derlying conditions may vary, an endometrial biopsy is most 
commonly performed in difficult to classify cases in order to 
rule out endometrial malignancy [1]. Initial workup  of AUB 
should include the most common causes which could be de-
scribed in classification system called PALM-COEIN — an acro-
nym for “Polyp, Adenomyosis, Leiomyoma, Malignancy (and 
hyperplasia), Coagulopathy, Ovulatory disorders, Endome-
trial, Iatrogenic and Not otherwise classified” [2].  For most 
gynecologists in an outpatient setting, the initial step is most 
often to find or exclude intrauterine structural abnormali-
ties, the so called “PALM” conditions. Typically the diagnostic 
options include transvaginal sonographic imaging, office 
endometrial sampling, and hysteroscopy [1, 2]. 
Endometrial cancer (EC) is currently the most common 
malignancy of the female genital tracts and occurs in 3.7–
17.9% of postmenopausal women who present with uterine 
bleeding [3].  The survival rates are high because in about 73% 
of cases cancer is diagnosed in stage I of clinical progression 
according to FIGO. Appropriate EC staging before operative 
procedures is mandatory to plan effective and tailored surgi-
cal treatment. In case of abnormal uterine bleeding, curettage 
was regarded to be the gold diagnostic standard for many 
decades [4]. The aim of our study was to analyze the available 
current status of knowledge regarding the possibility of neo-
plastic cell spread in the peritoneal cavity in the course of hys-
teroscopy performed in women with endometrial cancer. We 
searched PubMed, Ovid, Medline and Scopus databases for 
data published in the years 1985–2017. The following brows-
ing criteria, so called “Medical Subject Headings” or “MeSH 
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headings”: hysteroscopy, endometrial cancer, intraperitoneal 
or metastatic spread were used to find relevant papers. We 
have selected English language articles concerning groups 
of women with abnormal uterine bleeding diagnosed with 
sonography, endometrial biopsy and hysteroscopy as well as 
meta-analyses regarding the evaluation of risk of metastases 
of neoplastic cells into peritoneal cavity during hysteroscopic 
procedure in women with endometrial cancer.  
THE USE OF TRANSVAGINAL SONOGRAPHY 
IN WOMEN WITH ABNORMAL  
UTERINE BLEEDING
Transvaginal ultrasound of the uterus is currently the 
most commonly used non-invasive imaging method that 
has become the standard of care in evaluation of women 
with abnormal uterine bleeding, both in the pre- and post-
menopausal period. Several older and newer studies sug-
gested that the endometrium thickness < 4 mm as practically 
excluding the presence of endometrial cancer in a group of 
postmenopausal women with abnormal uterine bleeding 
who were not using hormone replacement therapy and, at 
the same time, was suggestive of atrophy [5, 6]. In patients us-
ing hormone replacement therapy and the thickness of endo-
metrium higher than 4.0 mm, histopathological evaluation of 
the endometrium should be considered. According to other 
data, the threshold of endometrium thickness indicating the 
necessity of performing a microscopic examination is 5.0 mm 
[6].  However, it should be clearly stated that there were also 
individual cases described in which endometrial cancer de-
veloped with endometrium thickness of less than 4.0 mm. 
Endometrial thickness is not the only parameter that may 
suggest the presence of proliferative process within the uter-
us. Other prognostically significant sonographic features in 
the early diagnostics of endometrial cancer are: echostructure 
of endometrium, the presence of central endometrial echo, 
margins of endometrium, the presence or blurring of echo of 
the junction zone (linking endometrium and myometrium) 
and the presence and system of small blood vessels within 
endometrium [7]. Selected indicators for assessing blood 
flow in these vessels and uterine arteries may also be used 
in predicting the presence of endometrial cancer (Fig. 1). 
Three-dimensional ultrasound, which can be used for precise 
evaluation of not only the volume of endometrium but also, 
semi-quantitatively, the presence of vessels and blood flow 
allows for extension of diagnostic capabilities (Fig. 2). It is 
important to assess the depth of the infiltration of myome-
trium, parametrium and/or cervix in order to prepare a proper 
treatment plan and evaluate the stage of neoplastic progres-
sion [8, 9]. Unfortunately, even the most precise ultrasound 
examination does not allow for obtaining histopathological 
diagnosis of the uterine cavity lesions. It can only be helpful in 
the initial evaluation of the risk of the presence of neoplastic 
process. Still, histological examination is the only and ultimate 
method allowing the correct diagnosis that warrants targeted 
and the most appropriate treatment.
ROLE OF VARIOUS ENDOMETRIAL  
SAMPLING METHODS IN THE DIAGNOSIS  
OF ENDOMETRIAL CANCER   
Preoperative results of a histological examination con-
firming the presence of endometrial cancer may be obtained 
Figure 1.  Sonographic sagittal 2D section of the uterus showing 
vascularity of early stage endometrial cancer
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by collecting material with the use of fine needle aspiration 
biopsy, or by fractional dilatation  and curettage (D&C) of 
the cervical canal and uterine cavity, or with endoscopy, 
by performing hysteroscopy with collection of material 
from suspected sites within uterine cavity.  According to the 
results of recent metaanalysis performed by van Hanegem 
et al. [4], the sensitivity of endometrial sampling in women 
with postmenopausal bleeding to detect not only endo-
metrial cancer  but also atypical hyperplasia or benign 
endometrial  conditions like  intrauterine polyps, is lower 
than previously thought.  Endometrial biopsy performed for 
abnormal uterine bleeding evaluation using Pipelle device 
has the sensitivity of malignancy detection ranging from 
67% to 83.5% [4]. Although endometrial cancer in young 
women is very rare it can be unexpectedly detected at hys-
teroscopy during uterine cavity diagnosis due to multiple 
IVF failures. Moreover, a blind endometrial biopsy is also 
insufficient in cases when rare uterine malignancies could be 
suspected [10]. The probability that such biopsy will detect 
uterine leiomyosarcoma or other related abnormal patho-
logical intrauterine findings could probably be higher for 
postmenopausal women with uterine bleeding. However, 
even negative  endometrial biopsy results, particularly in 
pre-menopausal patients, should be interpreted with cau-
tion if clinical symptoms and/or imaging techniques rise 
a suspicion of uterine sarcoma.
HYSTEROSCOPY AND ENDOMETRIAL 
CANCER DIAGNOSIS
Diagnostic hysteroscopy (HSC) is a minimally invasive 
procedure regarded by many authors as simple and safe. The 
method is often used in the evaluation of women with infertil-
ity and/or abnormal uterine bleeding [11]. Hysteroscopy has 
high sensitivity of 67–96% and specificity in the detection of 
endometrial cancer [12–14]. Collection of material with the 
use of hysteroscopy is more precise in cancer diagnostics 
compared to fractional dilatation and curettage of uterine 
cavity [13]. During hysteroscopy uterine cavity is subjected 
to endoscopic visualization and tissue material is collected for 
histological examination under visual control. Dueholm et al. 
have recently evaluated visually several pattern parameters 
obtained with hysteroscopy and presented a scoring system 
for the prediction of malignancy which they have compared 
with subjective evaluation. Their scoring system called HYCA 
(HYsteroscopic CAncer) included unsmooth lesion surface, 
papillary projections, surface necrosis, “candy floss” necrosis, 
hyperintense white spots, irregular branching vessels, and ir-
regular distribution of irregular vessels. This system predicted 
uterine endometrial cancer with higher accuracy than subjec-
tive evaluation and had an AUC of 0.964. The authors have 
concluded that their systematic pattern assessment based 
on systematically defined terms and best parameters and 
combined in a HYCA scoring system could increase accuracy 
of endometrial cancer prediction [15]. Apparently, this new 
approach deserves further evaluation and external valida-
tion in a prospectively recruited group of unselected women 
with postmenopausal bleeding.
THE RISK OF ENDOMETRIAL CANCER 
INTRABDOMINAL SPREAD FOLLOWING 
DIAGNOSTIC HYSTEROSCOPY
Since the wide introduction of diagnostic hysteroscopy 
more than three decades ago several authors pointed out 
that hysteroscopic procedure may cause relocation of neo-
plastic cells through fallopian tubes to peritoneal cavity 
[16, 17]. Two diagrams showing this possibility are presented 
in Figure 3. The real hysteroscopy-related risk of clinical 
progression of the disease and decrease survival of patients 
with endometrial cancer is difficult to estimate [18, 19]. The 
introduction of high pressure gas or liquid used to distend 
uterine cavity during hysteroscopy could theoretically fa-
cilitate the spread of malignant cells into peritoneal cavity. 
In some studies gas pressures between 100–150 mm Hg 
caused cancer cells relocation both through cervix and fal-
lopian tubes [20, 21]. Figure 4 presents malignant endome-
Figure 3. Hysteroscopy diagram with endometrial cancer highlighted 
in red in the uterine cavity with visible cancer cells passing through 
the right fallopian tubes and flowing into the peritoneal cavity  
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trial cancer metastases found in the peritoneal cavity on 
cytological smears following hysteroscopy.   
Obermair et al. [23] compared patients who were di-
agnosed with endometrial cancer on the basis of uterine 
cavity dilatation and curettage or hysteroscopy. Peritoneal 
cytology was collected during the course of the procedure. 
The study results indicated more frequent positive result 
of cytological examination confirming cancer cells pres-
ence following hysteroscopy. Bradley et al. [18] studied 
a group of 256 women with endometrial cancer and found 
a significantly lower percentage of patients with abnormal 
result of peritoneal cytology in 204 cases diagnosed us-
ing dilatation and curettage compared to patients who 
had hysteroscopy (6.9% vs. 13.5%). These results suggested 
higher risk of endometrial cancer spread after hysteroscopy. 
Similar conclusions were drawn by Takac and Zegura [19], 
who studied a group of 146 women and found positive or 
suspected result of peritoneal cytology in 1.6% patients fol-
lowing dilatation and curettage (2/122) and in 12.5% (3/24) 
of women who had hysteroscopy. 
Lo et al. [20] also confirmed the presence of endome-
trial cancer cells in the peritoneal cavity after application 
of liquid during hysteroscopic uterine cavity evaluation. 
Increased pressure of fluids used in hysteroscopic procedure 
could be a significant risk factor that may contribute to 
mechanical transfer of endometrial cancer cells through fal-
lopian tubes. Baker and Adamson [21] as well as Leveque et 
al. [22] used high pressure liquid and observed that pressure 
values of 150 mmHg affected positive results of cytological 
examination in 37% cases compared to 1% positive results 
when using pressure values below 100 mmHg. Polyzos et 
al. [23] in a meta-analysis of 9 clinical studies, in which they 
analyzed data from 1015 patients with endometrial cancer 
found that increased risk of metastasis of neoplastic cells to 
peritoneal cavity occurred in women subjected to hysteros-
copy with fluid pressure higher than 100 mmHg. 
In a large meta-analysis of almost 3000 women diag-
nosed with endometrial cancer, Chang et al. [24] found 
that hysteroscopy could increase the risk of metastases 
of neoplastic cells in the peritoneal cavity. The results of 
this meta-analysis also indicated that the higher statisti-
cal risk of metastases was associated with the use of fluid 
medium predominantly in women with advanced stages 
of endometrial cancer. Based on these results, the authors 
concluded that hysteroscopy as a diagnostic procedure 
should be recommended mainly in cases of early stages of 
endometrial cancer.  
Baker and Adamson [21] observed significantly lower 
number of endometrial cells in abdominal cavity after ap-
plying lower liquid pressure, that is < 70 mm Hg, in course 
of hysteroscopy. De Sousa Damiao et al. [25] also analyzed 
the influence of various values of pressure used during 
endoscopic procedures. They suggested using pressure 
lower than 80 mm Hg and carbon dioxide in course of gas 
hysteroscopy as well as collection of peritoneal cytology 
both before and after the diagnostic procedure.  The results 
obtained by these authors indicate that in both cases no 
endometrial cells were found in any patient subjected to cy-
tological examination of peritoneum. Thus, it seems that gas 
hysteroscopy using pressure below 80 mmHg and carbon 
dioxide appears to be a safe diagnostic technique in patients 
with suspected endometrial cancer.  Similar data were pre-
sented by Cicinelli et al. [26] on the basis of a randomized 
clinical study of a group of 140 women subjected to 5 years’ 
observation after diagnostic hysteroscopy procedure using 
liquid under pressure lower than 70 mmHg. These authors 
did not observe intraperitoneal metastasis of endometrial 
cancer cells in course of the diagnostic procedure and did 
not find increased risk of relapse of cancer within 5 years of 
observation [26].  
Selvaggi et al. [27] studied a group of 147 women with 
endometrial cancer divided into groups who had either 
dilation and curettage, or D&C followed by hysteroscopy 
or only hysteroscopy. No statistically significant differences 
were observed in the frequency of positive cytological ex-
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amination of peritoneum and in microscopic evaluation of 
intraperitoneal metastases in relation to the applied three 
different diagnostic procedures.  In 3 of 39 patients (7%) 
who underwent hysteroscopy, cytological examination re-
vealed the presence of neoplastic cells. This percentage is 
much lower than 12.5% of positive cytology cases found in 
the study published by Takac and Zegura [19]. It must be 
stressed that despite a series of reports suggesting a possi-
ble correlation between the application of hysteroscopy and 
the presence of cancer cells in peritoneal cavity, it cannot 
be clearly decided whether a positive result of cytological 
examination is associated with hysteroscopy or whether 
endometrial cells are found in peritoneal cavity even without 
any diagnostic procedure [28]. 
To date, no convincing studies on hysteroscopic fluid 
pressure and possible dispersal of cancer cells and their im-
plantation with intraperitoneal proliferation of endometrial 
cancer have been published. An interesting hypothesis has 
been presented by Biewenga et al. [29] who have suggested 
that there is no direct relationship between endometrial 
cancer cells spread during hysteroscopy and possible cancer 
dissemination as the positive cytology is only a transient 
phenomenon. Their study indicated that hysteroscopy was 
a method that did not affect the presence of cancer cells 
in peritoneal cavity and the progression of the disease in 
patients with FIGO stage I endometrial cancer [29]. These 
Authors have also observed that intraperitoneal cytology 
in women with endometrial cancer was negative follow-
ing hysteroscopy and after allowing to elapse a certain 
period of time. It is currently not known which molecular 
mechanisms may allow endometrial cancer cells found in 
the peritoneal cavity to become active after different periods 
of time. Kudela and Pilka [30] studied the influence of dilata-
tion  and curettage on the results of cytological examination 
of cells obtained from peritoneal cavity. The authors found 
positive results of cytology in 30.3% women subjected to 
endoscopy compared to 33.9% patients who underwent 
fractional curettage of cervical canal and uterine cavity. 
Soucie et al. [31] observed that hysteroscopy did not af-
fect further development of stage III progression of endome-
trial cancer. Also Dvorska et al. [32], in a retrospective study, 
found that hysteroscopy did not affect the risk of endome-
trial cancer metastasis in peritoneal cavity and prognosis for 
patients with endometrial cancer. In the most recent study, 
Dovnik et al [33] compared the results of cytological smears 
in patients undergoing initial diagnosis of endometrial pa-
thology using hysteroscopy and D&C. In their study they 
found the conclusion that there were no differences in the 
case of positive peritoneal smears between both groups, 
but in women with FIGO stage 1 of EC hysteroscopy was 
a reason of a significantly higher frequency of positive peri-
toneal cytology relative to D&C, (HSC = 12.8%; D&C = 3.4%; 
p = 0.046). In another recent analysis performed by Chen 
et al. [40] suggested that diagnostic hysteroscopy increases 
the frequency of positive peritoneal smears collected dur-
ing the surgery in patients with second type of endometrial 
cancer. A positive peritoneal cytology was found in 27.5% 
patients diagnosed with hysteroscopy and in 5% diagnosed 
with D&C. No differences in recurrence location were found 
between these two groups of women and no differences 
were observed in median survival times (60months for HSC 
group vs. 70 months for D&C group). 
In summary, several lines of evidence suggest that en-
dometrial cancer cells seem to be more likely to die than to 
disseminate and produce cancer recurrence following hyst-
eroscopy [17, 18, 25, 27]. However, this hypothesis needs to 
be confirmed in a well-designed prospective future stud-
ies. The analysis of data published to date shows that there 
is no basis for explicit conclusion that hysteroscopy leads 
to neoplastic metastases in women diagnosed with endo-
metrial cancer. The results of the presented studies indicate 
that endoscopic procedure is a safe way of visualization of 
the uterine cavity, and also can be considered as a safe tool 
in the diagnostics of endometrial cancer.  Hysteroscopy does 
not seem to significantly affect cancer cell intraabdominal 
spread and progression of endometrial cancer to a higher 
stage of clinical advancement. No studies so far have con-
firmed increased risk of endometrial cancer metastases 
when low pressure of the uterine cavity dilating medium 
was used. Some authors indicate that there is a possibil-
ity of such risk in women with type II endometrial cancer, 
however, with no influence patient survival [33]. Due to the 
above mentioned reasons further prospective studies are 
necessary in order to verify and determine the influence 
of hysteroscopy on the metastasis of endometrial cancer.  
CONCLUSIONS
Diagnostic hysteroscopy performed in women with 
endometrial cancer, especially in its early stages, is a very 
useful, efficient and safe diagnostic method.
The distension media used for endoscopic procedures 
in the uterine cavity must be strictly controlled for relatively 
low pressures to prevent the increase in risk of endometrial 
cancer intraperitoneal spread.
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